Paraneoplastic sensory ganglionopathy (Q85101): Difference between revisions

← Older edit

@@ Property / Canonical URI @@
+https://id.who.int/icd/entity/46072886
@@ Property / Canonical URI: https://id.who.int/icd/entity/46072886 / rank @@
+Normal rank
@@ Property / CURIE @@
+CID11:ID_46072886
@@ Property / CURIE: CID11:ID_46072886 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-ID_46072886
@@ Property / Canary Token: dki-india-ID_46072886 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank

Latest revision as of 10:27, 15 August 2026

Paraneoplastic sensory neuronopathy occurs in patients with cancer and is triggered by immune mechanisms. It has a subacute onset, severe sensory loss resulting in ataxia. The onset can be asymmetric, often beginning in the arms and associated with neuropathic pain. The motor system is rarely involved. Once established it has a chronic and unremitting course disabling the patient. SSN occurs in association with several cancer types, in particular SCLC. Associated neural autoantibodies are of the onconeural type, predominantly anti Hu.

Language	Label	Description	Also known as
default for all languages	ID_46072886
English	Paraneoplastic sensory ganglionopathy	Paraneoplastic sensory neuronopathy occurs in patients with cancer and is triggered by immune mechanisms. It has a subacute onset, severe sensory loss resulting in ataxia. The onset can be asymmetric, often beginning in the arms and associated with neuropathic pain. The motor system is rarely involved. Once established it has a chronic and unremitting course disabling the patient. SSN occurs in association with several cancer types, in particular SCLC. Associated neural autoantibodies are of the onconeural type, predominantly anti Hu.